Reduced Drug Metabolism in Cancer Patients with Inflammation
Author Information
Author(s): Rivory L P, Slaviero K A, Clarke S J
Primary Institution: Sydney Cancer Centre, University of Sydney
Hypothesis
The study aims to assess cytochrome P450 3A function in patients with advanced cancer and its relation to the acute-phase response.
Conclusion
Cancer patients with an acute-phase response have reduced drug metabolism, which may affect chemotherapy safety.
Supporting Evidence
- Cancer patients with an acute-phase response had a 30% reduction in drug metabolism compared to controls.
- The reduction in CYP3A function was independent of tumor type.
- Serum C-reactive protein levels correlated significantly with CYP3A activity.
Takeaway
When cancer patients get sick, their bodies don't process medicine as well, which can make treatments less safe.
Methodology
The study evaluated hepatic cytochrome P450 3A function using the erythromycin breath test and measured inflammatory markers in serum.
Potential Biases
Potential bias due to co-medication affecting CYP3A activity.
Limitations
The study was conducted at a single center and may not be generalizable to all cancer patients.
Participant Demographics
Participants were mostly lung and breast cancer patients, aged 38 to 83, with a median age of 64 years, and included 21 males and 19 females.
Statistical Information
P-Value
0.0062
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website